pH4HIF
Financiado
Effect of pH on colloidal structures in human intestinal fluids and intestinal a...
Effect of pH on colloidal structures in human intestinal fluids and intestinal absorption of anticancer drugs
Oral administration followed by intestinal absorption is the preferred way to deliver drugs to the body. Therefore, estimating thecorrect oral dose to achieve a therapeutic effect is an important challenge when developing drug pro...
Oral administration followed by intestinal absorption is the preferred way to deliver drugs to the body. Therefore, estimating thecorrect oral dose to achieve a therapeutic effect is an important challenge when developing drug products. Predicting intestinal drugabsorption needs to consider multiple influencing factors, including properties of the drug, the formulation, and the human intestinalfluids (HIF). One of the critical factors of HIF is pH, as it may influence intestinal drug absorption both directly and indirectly. The directeffect of pH on a drug’s ionisation state and, subsequently, intestinal absorption is widely known. However, the effect of pH on thesolubilisation and absorption of lipophilic drugs by changing the colloidal structures present in HIF, has not yet been systematicallyanalysed.Understanding this indirect pH effect is especially needed to improve dose predictions for drugs with a narrow therapeutic windowsuch as anticancer drugs, and address both inefficiency and potential side effects. The proposed project therefore aims to understandand predict the pH effect on colloidal structures in HIF and how it affects the absorption potential of anticancer drugs in both fastedand fed state conditions.To achieve its goal, the project combines the expertise of the host group at KU Leuven in absorption profiling using in vitro and invivo methods with the applicant’s experience in predictive in silico modelling. This approach will provide unique insights into theindirect pH effect on drug absorption and contribute to the development of in silico predictive models to guide the early-stageformulation and dose optimisation of anticancer drugs. As such, the project will have important value for pipelining new anticancerdrugs and will benefit the European Commission priorities for 2019-2024, such as the pharmaceutical strategy and Europe’s BeatingCancer Plan.
ver más
Duración del proyecto: 23 meses
Fecha Inicio: 2023-09-01
Fecha Fin: 2025-08-31
Fecha Fin: 2025-08-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-09-01
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-MSCA-2022-PF-01-01:
MSCA Postdoctoral Fellowships 2022
Cerrada
hace 2 años
Líder del proyecto
KATHOLIEKE UNIVERSITEIT LEUVEN
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5